Sharp Therapeutics Corp. SHRX.V
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX-V · United States
Sharp Therapeutics Corp. is a preclinical-stage drug discovery company developing small molecule therapeutics for genetic diseases, headquartered in Pittsburgh, Pennsylvania. The company's CoreX technology suite and AlloChem compound library target compounds that correct mutational defects in diseases such as Gaucher's disease and Niemann-Pick Type C.
Key ratios
ReturnOnAssets TTM -1.06
ReturnOnAssets 2025 -1.06
ReturnOnAssets 2024 -0.52
ReturnOnAssets 2023 -0.96
ReturnOnEquity TTM -5.13
ReturnOnEquity 2025 -5.13
Recent news
Sharp Therapeutics Announces Closing of Non-Brokered Private Placement
2026-07-29 · Newsfile
Sharp Therapeutics Corp. Announces Results from Annual Meeting of Shareholders
2026-07-21 · Newsfile
Sharp Therapeutics Announces Non-Brokered Private Placement and Provides Operational Update
2026-07-15 · Newsfile
Sharp Therapeutics Announces Filing of Amended and Restated Management Information Circular and New Annual Meeting Date
2026-06-30 · Newsfile
Sharp Therapeutics Presents New Preclinical Data Supporting Novel Small-Molecule Therapeutic Approach for Niemann-Pick Disease Type C
2026-05-28 · GlobeNewswire
Sharp Therapeutics Announces Closing of Third Tranche of Unsecured Convertible Note Offering
2026-04-02 · BioSpace
Sharp Therapeutics Announces Private Placement of up to US$3.0 Million in Unsecured Convertible Notes
2026-02-02 · Newsfile Corp